Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

Leukemia

Volumn 30, Issue 6, 2016, Pages 1230-1236

  Krug, U ^a   Berdel, W E ^a   Gale, R P ^b   Haferlach, C ^c   Schnittger, S ^d   Muller Tidow C ^a,u   Braess, J ^e,v   Spiekermann, K ^e   Staib, P ^f,w   Beelen, D ^g   Serve, H ^h   Schliemann, C ^a   Stelljes, M ^a   Balleisen, L ⁱ   Maschmeyer, G ^j   Gruneisen A ^k   Eimermacher, H ^l   Giagounidis, A ^m,x   Rasche, H ⁿ   Hehlmann, R ^o   Lengfelder, E ^o   Thiel, E ^p   Reichle, A ^q   Aul, C ^m   Ludwig, W D ^r   Kern, W ^c   Haferlach, T ^c   Kopcke W ^s   Gorlich D ^s   Sauerland, M C ^s   Heinecke, A ^s   Wormann B J ^t,y   Hiddemann, W ^e   Buchner T ^a   more..

^a KLINIKUM LEVERKUSEN   (Germany)

^b CELGENE CORPORATION   (United States)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d University Hospital Großhadern ^*  (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ EVANGELISCHES KRANKENHAUS   (Germany)

^j KLINIKUM ERNST VON BERGMANN   (Germany)

^k VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^l Allgemeines Krankenhaus Hagen gem GmbH   (Germany)

^m Department of Pediatrics Helios Klinikum   (Germany)

ⁿ KLINIKUM BREMEN MITTE   (Germany)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^r HELIOS KLINIKUM BERLIN BUCH   (Germany)

^s UNIVERSITY OF MÜNSTER   (Germany)

^t KLINIKUM BRAUNSCHWEIG   (Germany)

^u MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^v Krankenhaus der Barmherzigen Bruder   (Germany)

^w Oncology and Palliative Care   (Germany)

^x MARIEN HOSPITAL DÜSSELDORF   (Germany)

^y German Society of Hematology and Oncology   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; TIOGUANINE; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; DANAZOL; TAMOXIFEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGRAFT; ARTICLE; AUTOGRAFT; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; INTENSIVE CARE; INTENTION TO TREAT ANALYSIS; LEUKEMIA REMISSION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; VERY ELDERLY; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AMINOGLUTETHIMIDE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DANAZOL; DISEASE-FREE SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MITOXANTRONE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TAMOXIFEN; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959456704     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.25     Document Type: Article

References (24)

1. Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009; 27: 61-69.
2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012; 30: 3604-3610.
4. Niederwieser D, Hoffmann VS, Krahl R, Berdel WE, Sauerland MC, Hiddemann W et al. Factors influencing complete remission (CR) rate in patients 4= 60 years with acute myeloid leukemia (AML): report from the German AML Intergroup Study. Blood 2012; 120(Suppl 21): S1 (abstract 128).
5. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
6. Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol 2014; 32: 288-296.
7. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.
8. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841-2851.
9. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259.
10. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-1248.
11. Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U et al. Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial. Blood 2015; 126(Suppl 23): S1 (abstract 222).
12. Löwenberg B, van Putten W, Theobald M, Gmür J, Verdonck L, Sonneveld P et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743-752.
13. Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119: 5367-5373.
14. Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission? Leukemia 2014; 28: 1949-1952.
15. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-223.
16. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978-2986.
17. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-708.
18. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649-1656.
19. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97: 1721-1231.
20. Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011; 118: 6037-6042.
21. Reiffers J, Gaspard MH, Maraninchi D, Michallet M, Marit G, Stoppa AM et al. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br J Haematol 1989; 72: 57-63.
22. Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996; 10: 1874-1882.
23. Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC et al. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial. Br J Haematol 2005; 128: 59-65.
24. Pfirrmann M, Ehninger G, Thiede C, Bornhaüser M, Kramer M, Röllig C et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012; 13: 207-214.